exhibit 10. 15certain confidential information contained in this document, marked by [ * * ], has been omitted because archerdx, inc. has determined the information ( i ) is not material and ( ii ) would likely cause competitive harm to archerdx, inc. if publicly disclosed. master services agreementby and betweenastrazeneca ab ( publ ) andarcherdx, inc2019page | 1master services agreementdefinitions41. services83standards94current good manufacturing practices ( “ gmp ” ). 95good laboratory practice96compensation97taxes118product security119confidentiality1310term and termination1311indemnification1512liability1813subcontracting1914expectations of third parties1915right to audit2016adverse event reporting requirements2117anti - bribery anti - corruption ( “ abac ” ) 2218amendments, changes and modifications2219ownership of results and background ipr2220error or delay in performance of the services2421reserved2422mediation2423arbitration2424assignment2525reserved2526no minimum commitment. 2527further assurance2528data privacy2529debarment2530reserved2631reserved2632reserved2633force majeure2634us physician sunshine act requirements2635human biological samples ( “ hbs ” ) 2736promotional policies2737publications2738representations, warranties and covenants2839reserved2940safety and security requirements2941travel and expenses2942reserved3043reserved3044reserved3045construction3046entire agreement and amendment30page | 2master services agreement47governing law3148jurisdiction3149miscellaneous31schedule 1 - statement of work - template34schedule 2 - rate card37schedule 3 - data protection and security requirements38schedule 4 - summary of astrazeneca promotional policies54schedule 5 – human biological samples56schedule 6 – key performance indicators ( service levels ) 61schedule 7 – design and reporting of essential and exploratory research objectives62page | 3master services agreementmaster services agreementthis